Biovica International Ab Class B · OMXSTO:BIOVIC_B

Biovica International Ab Class B — Q3 2025 Earnings Presentation

30 slides from Biovica International Ab Class B's earnings presentation, Mar 13, 2025

Slide 1: Biovica cover
Slide 2: Forward Looking-Statements Disclaimer
Forward Looking-Statements Disclaimer The Investor Presentation may contain certain statements that are forward-looking. These statements may refer in particular to the Company’s business strategies, its expansion and growth of operations, future events, trends or objectives and expectations, which
Slide 3: Q3 Interim Report
Q3 Interim Report Anders Rylander CEO Anders Morén CFO 3
Slide 5: Q&A Session
Q&A Session Financial Analysts on today’s call: • Johan Unnérus - RedEye • Chien-Hsun Lee & Dan Akschuti - Pareto Securities AG 5
Slide 7: DiviTum TKa
DiviTum® TKa An early indicator of cancer treatment effectiveness + References: http://biovica.com/technology/publications/ DiviTum® TKa cell proliferation provides quicker evaluation of cancer treatment efficacy.
Slide 8: Strong scientific evidence that is still growing!
Strong scientific evidence that is still growing! 30+ published and peer-reviewed articles Cancer Area Patients Nr. of studies Strong evidence supporting the use of Breast Cancer 3,039 14 DiviTum® TKa as a clinical biomarker Gastrointestinal 713 4 of CDK4/6i response Malignant Melanoma 86 2 Collabor
Slide 9: Large market potential in first application!
Large market potential in first application! • Key assumptions: $400 average sales price per test in US, prevalence according to Globocan 2022 • US go to market model: all 50 states served from Biovica CLIA Lab • Other markets: Partner model, where partner introduces DiviTum on the local market • Gr
Slide 11: Biovica Q3 Highlights
Biovica Q3 Highlights US: • New clinical results in early breast cancer opens a significant larger market. • Agreement signed with health-care giant. Use of DiviTum TKa has started (Feb) • CLIA lab now certified for all 50 states in US after New York approval. • Outcomes4Me collaboration – an excell
Slide 13: Sales Performance Q3
Sales Performance Q3 Revenue growth in Q3 24/25: IVD Tests (US) • 150% Q3 23/24 Sales per quarter $70 000 • 2% vs. Q2 24/25 $60 000 $50 000 Q3 quarter negatively affected by multiple $40 000 holidays when compared to Q2 $30 000 $20 000 January & February our best months so far! $10 000 $0 FY23/24 Q
Slide 14: DiviTum TKa in Early and Metastatic Setting Breast Cancer (HR+)
DiviTum TKa in Early and Metastatic Setting Breast Cancer (HR+) Early setting – 5-10 years Metastatic setting ~3 years Diagnosis Surgery Recurrence Neo- adjuvant Adjuvant therapy Metastatic therapy therapy ~16 tests over 5 years ~20 tests over 3 year per patient New DiviTum TKa utility Current DiviT
Slide 15: Health Care Giant Opportunity Update
Health Care Giant Opportunity Update Metastatic Breast Cancer Monitoring • Client bill agreement signed in December 2024. • Use of DiviTum has started for monitoring of metastatic breast cancer during February. Early Breast Cancer / Adjuvant Treatment Monitoring • Discussions are ongoing to implemen
Slide 16: Outcomes4Me Collaboration
Outcomes4Me Collaboration Patient group organization with >250.000 cancer patients that interacts with patients through their app. Objectives with collaboration • Amplify awareness of DiviTum® testing and its benefits in monitoring cancer treatment efficacy. • Enhancing patient advocacy by enabling
Slide 17: US Market go-to-market strategy development
US Market go-to market strategy development US Market Clinical Use BC NCI/NCCN Community Private Insurance & IDN’s Designated Oncologists Centers Biovica focus 1/3 of of cancer patients* 2/3 of cancer patients* 80% of current revenues 20% of current revenues High Value - Large volume - Biovica focus
Slide 19: The Pharma Services & Collaboration Business
The Pharma Services & Collaboration Business Supporting pharma companies developing new cancer therapies 1. Service & Kit Sales 2. CDx Collaborations 3. CDx Product Sales • Support during pre-clinical and • Co-development of complementary • CDx product on the market clinical trials phase diagnostic
Slide 21: Agreement with EuroBio Scientific ~60% of key markets in Europe
Agreement with EuroBio Scientific ~60% of key markets in Europe Agreement with EuroBio Scientific Covers BeNeLux, DACH & UK Corresponds to ~60% of potential on key markets in Europe Together with previous agreement, we now cover the key markets • Axlab: Nordics • Palex: Spain & Portugal
Slide 23: YTD Acc Net Sales by Quarter vs PY (KSEK)
YTD Acc Net Sales by Quarter vs PY (KSEK)
Slide 24: YTD US IVD Sales by Quarter (KSEK)
YTD US IVD Sales by Quarter (KSEK)
Slide 25: Q3 Sales 23/24 vs Q3 Sales 24/25 (KSEK)
Q3 Sales 23/24 vs Q3 Sales 24/25 (KSEK)
Slide 26: Cash flow Q3 23/24 vs Q3 24/25
Cash flow Q3 23/24 vs Q3 24/25 Operating Cashflow improved with SEK 5,3M vs same period last year.
Slide 28: Summary and upcoming milestones
Summary and upcoming milestones Key Achievements Upcoming milestones FDA 510(k) clearance. • Extending application to include Adjuvant Breast Cancer as LDT test from CLIA Lab CLIA lab & Medicare price. • Establish DiviTum TKa as standard of care at Commercial agreements covering ~70 hospitals. healt
Slide 29: Q&A Session
Q&A Session Financial Analysts on today’s call: • Johan Unnérus - RedEye • Chien-Hsun Lee & Dan Akschuti - Pareto Securities 33
Slide 30: Treatment decisions with greater confidence
f & TREATME! CISIONS WITH GREATER CONFIDEN‘ ‘J

Biovica International — Q3 2025 Earnings Presentation on 6ix

Biovica International Ab Class B — Q3 2025 Earnings Presentation

Slide 1: Biovica cover

Slide 2: Forward Looking-Statements Disclaimer

Slide 3: Q3 Interim Report

Slide 4: Agenda

Slide 5: Q&A Session

Slide 6: Biovica Introduction

Slide 7: DiviTum TKa

Slide 8: Strong scientific evidence that is still growing!

Slide 9: Large market potential in first application!

Slide 10: Q3 Highlights

Slide 11: Biovica Q3 Highlights

Slide 12: US Highlights

Slide 13: Sales Performance Q3

Slide 14: DiviTum TKa in Early and Metastatic Setting Breast Cancer (HR+)

Slide 15: Health Care Giant Opportunity Update

Slide 16: Outcomes4Me Collaboration

Slide 17: US Market go-to-market strategy development

Slide 18: Pharma Service Update

Slide 19: The Pharma Services & Collaboration Business

Slide 20: Europe Update

Slide 21: Agreement with EuroBio Scientific ~60% of key markets in Europe

Slide 22: Financial Update - Q3 2024/2025

Slide 23: YTD Acc Net Sales by Quarter vs PY (KSEK)

Slide 24: YTD US IVD Sales by Quarter (KSEK)

Slide 25: Q3 Sales 23/24 vs Q3 Sales 24/25 (KSEK)

Slide 26: Cash flow Q3 23/24 vs Q3 24/25

Slide 27: Summary & QA

Slide 28: Summary and upcoming milestones

Slide 29: Q&A Session

Slide 30: Treatment decisions with greater confidence